

**UTILITY PATENT APPLICATION TRANSMITTAL**  
**(Large Entity)**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.  
10308BTotal Pages in this Submission  
4**TO THE ASSISTANT COMMISSIONER FOR PATENTS**Box Patent Application  
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

**IMMUNOREACTIVE AND IMMUNOTHERAPEUTIC MOLECULES**

and invented by:

Leonard Harrison  
Margo Honeyman  
George Ray  
Andrew LewJ1040 U.S. PTO  
10/040815  
01/07/02If a **CONTINUATION APPLICATION**, check appropriate box and supply the requisite information:☐ Continuation ☒ Divisional ☐ Continuation-in-part (CIP) of prior application No.: 08/663,272

Which is a:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.:

Which is a:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.:

Enclosed are:

**Application Elements**

1. ☒ Filing fee as calculated and transmitted as described below
2. ☒ Specification having 30 pages and including the following:
  - a. ☒ Descriptive Title of the Invention
  - b. ☐ Cross References to Related Applications (if applicable)
  - c. ☐ Statement Regarding Federally-sponsored Research/Development (if applicable)
  - d. ☐ Reference to Microfiche Appendix (if applicable)
  - e. ☒ Background of the Invention
  - f. ☒ Brief Summary of the Invention
  - g. ☒ Brief Description of the Drawings (if drawings filed)
  - h. ☒ Detailed Description
  - i. ☒ Claim(s) as Classified Below
  - j. ☒ Abstract of the Disclosure

**UTILITY PATENT APPLICATION TRANSMITTAL**  
**(Large Entity)**

*(Only for new nonprovisional applications under 37 CFR 1.53(b))*

Docket No.  
10308B

Total Pages in this Submission  
4

**Application Elements (Continued)**

3. ☒ Drawing(s) *(when necessary as prescribed by 35 USC 113)*
- a. ☒ Formal                      Number of Sheets 4
- b. ☐ Informal                      Number of Sheets \_\_\_\_\_
4. ☒ Oath or Declaration
- a. ☐ Newly executed *(original or copy)*                      ☐ Unexecuted
- b. ☒ Copy from a prior application (37 CFR 1.63(d)) *(for continuation/divisional application only)*
- c. ☒ With Power of Attorney                      ☐ Without Power of Attorney
- d. ☐ DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s) named in the prior application,  
see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5. ☒ Incorporation By Reference *(usable if Box 4b is checked)*  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under  
Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby  
incorporated by reference therein.
6. ☐ Computer Program in Microfiche *(Appendix)*
7. ☒ Nucleotide and/or Amino Acid Sequence Submission *(if applicable, all must be included)*
- a. ☒ Paper Copy
- b. ☐ Computer Readable Copy *(identical to computer copy)*
- c. ☐ Statement Verifying Identical Paper and Computer Readable Copy

**Accompanying Application Parts**

8. ☐ Assignment Papers *(cover sheet & document(s))*
9. ☐ 37 CFR 3.73(B) Statement *(when there is an assignee)*
10. ☐ English Translation Document *(if applicable)*
11. ☒ Information Disclosure Statement/PTO-1449                      ☐ Copies of IDS Citations
12. ☒ Preliminary Amendment
13. ☒ Acknowledgment postcard
14. ☒ Certificate of Mailing
- ☐ First Class    ☒ Express Mail *(Specify Label No.):* EV 052766565 US

**UTILITY PATENT APPLICATION TRANSMITTAL**  
**(Large Entity)**

*(Only for new nonprovisional applications under 37 CFR 1.53(b))*

Docket No.  
10308B

Total Pages in this Submission  
4

**Accompanying Application Parts (Continued)**

15. ☐ Certified Copy of Priority Document(s) *(if foreign priority is claimed)*

16. ☒ Additional Enclosures *(please identify below):*

**Request to Use Computer Readable Form of Sequence Listing from Another Application Under  
37 C.F.R. 1.821(e)  
Verification**

**Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)**

17. ☐ Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

**Warning**

***An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.***

**UTILITY PATENT APPLICATION TRANSMITTAL**  
**(Large Entity)**

*(Only for new nonprovisional applications under 37 CFR 1.53(b))*

Docket No.  
10308B

Total Pages in this Submission  
4

**Fee Calculation and Transmittal**


**CLAIMS AS FILED**

For	#Filed	#Allowed	#Extra	Rate	Fee
<b>Total Claims</b>	35	- 20 =	15	x \$18.00	\$270.00
<b>Indep. Claims</b>	4	- 3 =	1	x \$84.00	\$84.00
<b>Multiple Dependent Claims (check if applicable)</b> <input checked="" type="checkbox"/>					\$280.00
<b>BASIC FEE</b>					\$740.00
<b>OTHER FEE (specify purpose)</b> _____					\$0.00
<b>TOTAL FILING FEE</b>					\$1,374.00

- ☒ A check in the amount of **\$1,374.00** to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge and credit Deposit Account No. **19-1013/SSMP** as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_ as filing fee.
- ☒ Credit any overpayment.
- ☒ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
- ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

Dated: January 7, 2002

PIB/LP:dg  
cc:

  
\_\_\_\_\_  
Signature  
**Leopold Presser**  
Registration No. 19,827  
**SCULLY, SCOTT, MURPHY & PRESSER**  
400 Garden City Plaza  
Garden City, NY 11530  
(516) 742-4343

**CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)**Applicant(s): **Leonard Harrison, et al.**

Docket No.

**10308B**

Serial No.

**Unassigned**

Filing Date

**Herewith**

Examiner

**Unassigned**

Group Art Unit

**Unassigned**Invention: **IMMUNOREACTIVE AND IMMUNOTHERAPEUTIC MOLECULES**

I hereby certify that the following correspondence:

**New Divisional Application***(Identify type of correspondence)*

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on

**January 7, 2002***(Date)***Michelle Mustafa***(Typed or Printed Name of Person Mailing Correspondence)**(Signature of Person Mailing Correspondence)***EV 052766565 US***("Express Mail" Mailing Label Number)***Note: Each paper must have its own certificate of mailing.**

**CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)**Applicant(s): **Leonard Harrison, et al.**

Docket No.

**10308B**Serial No.  
**Unassigned**Filing Date  
**Herewith**Examiner  
**Unassigned**Group Art Unit  
**Unassigned**Invention: **IMMUNOREACTIVE AND IMMUNOTHERAPEUTIC MOLECULES**

I hereby certify that the following correspondence:

**New Divisional Application***(Identify type of correspondence)*

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on


**January 7, 2002***(Date)***Michelle Mustafa***(Typed or Printed Name of Person Mailing Correspondence)**(Signature of Person Mailing Correspondence)***EV 052766565 US***("Express Mail" Mailing Label Number)***Note: Each paper must have its own certificate of mailing.**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****Applicants:** Leonard Harrison, et al**Examiner:** Unassigned**Serial No.:** Unassigned**Docket:** 10308B**Filed:** Herewith**Dated:** January 7, 2002**For:** IMMUNOREACTIVE AND  
IMMUNOTHERAPEUTIC MOLECULESAssistant Commissioner for Patents  
Washington, DC 20231**VERIFICATION**


Sir:

I hereby state that the contents of the paper copy of the Sequence Listing and the computer readable form (CRF) filed in Application Serial No. 08/663,272 submitted on September 3, 1997 are identical.

Respectfully submitted,

  
Leopold Presser  
Registration No. 19,827SCULLY, SCOTT, MURPHY & PRESSER  
400 Garden City Plaza  
Garden City, New York 11530  
(516) 742-4343  
PIB/LP:dg**CERTIFICATE OF MAILING BY "EXPRESS MAIL"****"Express Mail" Mailing Label Number:** EV 052766565 US  
**Date of Deposit:** January 7, 2002

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents and Trademarks, Washington, D.C. 20231.

**Dated:** January 7, 2002  
Michelle Mustafa

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****Applicants:** Leonard Harrison, et al**Examiner:** Unassigned**Serial No.:** Unassigned**Docket:** 10308B**Filed:** Herewith**Dated:** January 7, 2002**For:** IMMUNOREACTIVE AND  
IMMUNOTHERAPEUTIC MOLECULESAssistant Commissioner for Patents  
Washington, DC 20231**REQUEST TO USE COMPUTER READABLE FORM OF SEQUENCE  
LISTING FROM ANOTHER APPLICATION UNDER 37 C.F.R. §1.821(e)**

Sir:

The computer readable form in the present application, is identical with that filed in 08/663,272 submitted on September 3, 1997. In accordance with 37 C.F.R. §1.821(e), please use the computer readable form filed in the '272 application on September 3, 1997 as the computer readable form for the

---

**CERTIFICATE OF MAILING BY "EXPRESS MAIL"****"Express Mail" Mailing Label Number: EV 052766565 US****Date of Deposit: January 7, 2002**


I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents and Trademarks, Washington, D.C. 20231.

**Dated: January 7, 2002**  
Michelle Mustafa



instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing is included in a separately filed preliminary amendment filed in the '272 application on September 3, 1997.

Respectfully submitted,



Leopold Presser  
Registration No. 19,827

SCULLY, SCOTT, MURPHY & PRESSER  
400 Garden City Plaza  
Garden City, New York 11530  
(516) 742-4343

PIB/LP:dg

2025 OCT 13 10 43 AM '97